The US Federal Drug Administration approves drug-maker Ranbaxy Laboratories to market and manufacture Ramipril, which is used in the treatment of cardiovascular diseases.
The pharmaceuticals company has received final nod from US Food and Drug Administration (US FDA) for Ramipril capsules, it said in a filing to the Bombay Stock Exchange.
Ranbaxy Receives US Approval for Manufacturing and Marketing Ramipiril
India’s Ranbaxy Laboratories has received the nod of U.S. Food and Drug Administration to manufacture and market ramipril capsules.
India’s Ranbaxy Laboratories has received the nod of U.S. Food and Drug Administration to manufacture and market ramipril capsules.
Ramipril is a bio-equivalent to King Pharmaceuticals' Altace drug, which can be used to treat hypertension.
The drug will be available in the strength of 5mg and 10mg capsules.
Ranbaxy may Move Away from Generics Following Merger With Japanese Multinational Daiichi
India’s Ranbaxy could move away from generics following its merger with the Japanese multinational Daaichi Sankyo.
India’s Ranbaxy could move away from generics following its merger with the Japanese multinational Daaichi Sankyo.
Shares of Ranbaxy were trading at 139.70 rupees, down 1.13 percent on the Bombay Stock Exchange.
Advertisement
Indian Opposition Leader Denounces Ranbaxy Merger With Japanese Multi-national
L.K.Advani, a possible Prime Ministerial candidate after next year’s national elections, has denounced the merger of the Ranbaxy Laboratories, Indian pharma major with a Japanese MNC as unacceptable.
L.K.Advani, a possible Prime Ministerial candidate after next year’s national elections, has denounced the merger of the Ranbaxy Laboratories, Indian pharma major with a Japanese MNC as unacceptable.
ARU/L
